메뉴 건너뛰기




Volumn 25, Issue 6, 2013, Pages 503-514

New oral anticoagulants: An emergency department overview

Author keywords

Apixaban; Dabigatran; NOAC; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIFAB; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; KANOKAD; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

EID: 84889664781     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/1742-6723.12156     Document Type: Article
Times cited : (3)

References (42)
  • 1
    • 0003266285 scopus 로고    scopus 로고
    • THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran
    • Wahlander K, Lapidus L, Olsson C. THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran. Blood 2001; 98: 268A-269.
    • (2001) Blood , vol.98
    • Wahlander, K.1    Lapidus, L.2    Olsson, C.3
  • 2
    • 0141636587 scopus 로고    scopus 로고
    • A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
    • Eriksson H, Wahlander K, Gustafsson D etal. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. 2003; 1: 41-47.
    • (2003) J. Thromb. Haemost. , vol.1 , pp. 41-47
    • Eriksson, H.1    Wahlander, K.2    Gustafsson, D.3
  • 3
    • 57849143295 scopus 로고    scopus 로고
    • Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran
    • Agnelli G, Eriksson BI, Cohen AT etal. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb. Res. 2009; 123: 488-497.
    • (2009) Thromb. Res. , vol.123 , pp. 488-497
    • Agnelli, G.1    Eriksson, B.I.2    Cohen, A.T.3
  • 4
    • 0038185371 scopus 로고    scopus 로고
    • Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study
    • Petersen P, Grind M, Adler J, Investigators SI. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 2003; 41: 1445-1451.
    • (2003) J. Am. Coll. Cardiol. , vol.41 , pp. 1445-1451
    • Petersen, P.1    Grind, M.2    Adler, J.3    Investigators, S.I.4
  • 5
    • 33746287448 scopus 로고    scopus 로고
    • Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran
    • Harenberg J, Jorg I, Weiss C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol. 2006; 25: 165-169.
    • (2006) Int. J. Toxicol. , vol.25 , pp. 165-169
    • Harenberg, J.1    Jorg, I.2    Weiss, C.3
  • 6
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S etal. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 7
    • 79952301326 scopus 로고    scopus 로고
    • Apixaban in patients with atrial fibrillation
    • Connolly SJ, Eikelboom J, Joyner C etal. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011; 364: 806-817.
    • (2011) N. Engl. J. Med. , vol.364 , pp. 806-817
    • Connolly, S.J.1    Eikelboom, J.2    Joyner, C.3
  • 8
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J etal. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
    • (2011) N. Engl. J. Med. , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 9
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • Granger CB, Alexander JH, McMurray JJ etal. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981-992.
    • (2011) N. Engl. J. Med. , vol.365 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 10
    • 71849117615 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK etal. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009; 361: 2342-2352.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 11
  • 12
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • Investigators E-P, Buller HR, Prins MH etal. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012; 366: 1287-1297.
    • (2012) N. Engl. J. Med. , vol.366 , pp. 1287-1297
    • Investigators, E.-P.1    Buller, H.R.2    Prins, M.H.3
  • 13
    • 84880327613 scopus 로고    scopus 로고
    • Oral apixaban for the treatment of acute venous thromboembolism
    • Agnelli G, Buller HR, Cohen A etal. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 2013; 369: 799-808.
    • (2013) N. Engl. J. Med. , vol.369 , pp. 799-808
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3
  • 14
    • 84874003257 scopus 로고    scopus 로고
    • Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK etal. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 2013; 368: 709-718.
    • (2013) N. Engl. J. Med. , vol.368 , pp. 709-718
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 15
    • 84873596181 scopus 로고    scopus 로고
    • Apixaban for extended treatment of venous thromboembolism
    • Agnelli G, Buller HR, Cohen A etal. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 2013; 368: 699-708.
    • (2013) N. Engl. J. Med. , vol.368 , pp. 699-708
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3
  • 16
    • 35348879239 scopus 로고    scopus 로고
    • Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
    • Ezekowitz MD, Reilly PA, Nehmiz G etal. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am. J. Cardiol. 2007; 100: 1419-1426.
    • (2007) Am. J. Cardiol. , vol.100 , pp. 1419-1426
    • Ezekowitz, M.D.1    Reilly, P.A.2    Nehmiz, G.3
  • 17
    • 84889643720 scopus 로고    scopus 로고
    • CARM. [Cited 29 Oct 2013.] Available from
    • CARM. [Cited 29 Oct 2013.] Available from URL: http://www.medsafe.govt.nz/consumers/Safety-of-Medicines/UpdateOnPradaxa.asp
  • 18
    • 84889640667 scopus 로고    scopus 로고
    • ADRAC. [Cited 29 Oct 2013.] Available from
    • ADRAC. [Cited 29 Oct 2013.] Available from URL: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm#ae-reports
  • 20
    • 84889635153 scopus 로고    scopus 로고
    • Early reversal with prothrombin complex concentrate in vitamin K antagonist-treated patients with severe haemorrhage is associated with decreased mortality. ISTH Abstracts. Amsterdam
    • Vigué B. Early reversal with prothrombin complex concentrate in vitamin K antagonist-treated patients with severe haemorrhage is associated with decreased mortality. ISTH Abstracts. Amsterdam, 2013.
    • (2013)
    • Vigué, B.1
  • 21
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
    • (2011) Circulation , vol.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, J.C.4    Buller, H.R.5    Levi, M.6
  • 22
    • 84858755308 scopus 로고    scopus 로고
    • The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation
    • van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 2011; 118: 1004-04.
    • (2011) Blood , vol.118 , pp. 1004-1004
    • van Ryn, J.1    Schurer, J.2    Kink-Eiband, M.3    Clemens, A.4
  • 23
    • 84889670630 scopus 로고    scopus 로고
    • Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban. ISTH Abstracts. OC 36.5.
    • Levi M. Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban. ISTH Abstracts. 2013: OC 36.5.
    • (2013)
    • Levi, M.1
  • 24
    • 84864370719 scopus 로고    scopus 로고
    • Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers
    • Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 2012; 108: 217-224.
    • (2012) Thromb. Haemost. , vol.108 , pp. 217-224
    • Marlu, R.1    Hodaj, E.2    Paris, A.3    Albaladejo, P.4    Cracowski, J.L.5    Pernod, G.6
  • 25
    • 84655176578 scopus 로고    scopus 로고
    • Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model
    • Godier A, Miclot A, Le Bonniec B etal. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
    • (2012) Anesthesiology , vol.116 , pp. 94-102
    • Godier, A.1    Miclot, A.2    Le Bonniec, B.3
  • 26
    • 84886258579 scopus 로고    scopus 로고
    • Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
    • Martin AC, Le Bonniec B, Fischer AM etal. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int. J. Cardiol. 2013; 168: 4228-4233.
    • (2013) Int. J. Cardiol. , vol.168 , pp. 4228-4233
    • Martin, A.C.1    Le Bonniec, B.2    Fischer, A.M.3
  • 27
    • 84874256149 scopus 로고    scopus 로고
    • Abstracts from the emerging science series, June 20, 2012
    • Escolar E. Abstracts from the emerging science series, June 20, 2012. Circulation 2012; 126: 520-521.
    • (2012) Circulation , vol.126 , pp. 520-521
    • Escolar, E.1
  • 28
    • 67849124919 scopus 로고    scopus 로고
    • Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370)
    • Abstract 0370.
    • van Ryn J, Ruehl D, Priepke H etal. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370). Haematologica 2008; 93: Abstract 0370.
    • (2008) Haematologica , vol.93
    • van Ryn, J.1    Ruehl, D.2    Priepke, H.3
  • 29
    • 84856214360 scopus 로고    scopus 로고
    • Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran
    • Zhou W, Schwarting S, Illanes S etal. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
    • (2011) Stroke , vol.42 , pp. 3594-3599
    • Zhou, W.1    Schwarting, S.2    Illanes, S.3
  • 30
    • 84879549154 scopus 로고    scopus 로고
    • Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates
    • ASH Annual Meeting Abstracts, 112: 3825.
    • Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. ASH Annual Meeting Abstracts 2008; 112: 3825.
    • (2008)
    • Gruber, A.1    Marzec, U.M.2    Buetehorn, U.3    Hanson, S.4    Perzborn, E.5
  • 31
    • 84865793090 scopus 로고    scopus 로고
    • Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
    • Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J. Thromb. Haemost. 2012; 10: 1830-1840.
    • (2012) J. Thromb. Haemost. , vol.10 , pp. 1830-1840
    • Lambourne, M.D.1    Eltringham-Smith, L.J.2    Gataiance, S.3    Arnold, D.M.4    Crowther, M.A.5    Sheffield, W.P.6
  • 32
    • 84870776429 scopus 로고    scopus 로고
    • Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system
    • Van Ryn J, Neubauer M, Flieg R etal. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematol. 2010; 95: 293-93.
    • (2010) Haematol. , vol.95 , pp. 293-293
    • Van Ryn, J.1    Neubauer, M.2    Flieg, R.3
  • 33
    • 84875926001 scopus 로고    scopus 로고
    • Effective elimination of dabigatran by haemodialysis A phase I single-centre study in patients with end-stage renal disease
    • Khadzhynov D, Wagner F, Formella S etal. Effective elimination of dabigatran by haemodialysis A phase I single-centre study in patients with end-stage renal disease. Thromb. Haemost. 2013; 109: 596-605.
    • (2013) Thromb. Haemost. , vol.109 , pp. 596-605
    • Khadzhynov, D.1    Wagner, F.2    Formella, S.3
  • 34
    • 84861975957 scopus 로고    scopus 로고
    • An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models
    • Van Ryn J, Litzenburger T, Waterman A etal. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models. J. Thromb. Haemost. 2011; 9: 110-10.
    • (2011) J. Thromb. Haemost. , vol.9 , pp. 110-110
    • Van Ryn, J.1    Litzenburger, T.2    Waterman, A.3
  • 35
    • 84878460192 scopus 로고    scopus 로고
    • A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
    • Lu GM, DeGuzman FR, Hollenbach SJ etal. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 2013; 19: 446-451.
    • (2013) Nat. Med. , vol.19 , pp. 446-451
    • Lu, G.M.1    DeGuzman, F.R.2    Hollenbach, S.J.3
  • 36
    • 75549083726 scopus 로고    scopus 로고
    • Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center
    • Sartori MT, Imbergamo S, Zanon E etal. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center. Clin. Appl. Thromb. Hemost 2009; 15: 628-635.
    • (2009) Clin. Appl. Thromb. Hemost , vol.15 , pp. 628-635
    • Sartori, M.T.1    Imbergamo, S.2    Zanon, E.3
  • 37
    • 0017252003 scopus 로고
    • Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies
    • Smith TW, Haber E, Yeatman L, Butlern VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N. Engl. J. Med. 1976; 294: 797-800.
    • (1976) N. Engl. J. Med. , vol.294 , pp. 797-800
    • Smith, T.W.1    Haber, E.2    Yeatman, L.3    Jr Butlern, V.P.4
  • 38
    • 84876684507 scopus 로고    scopus 로고
    • In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran
    • van Ryn J, Litzenburger T, Gan GF, Coble K, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood 2012; 120: 3418.
    • (2012) Blood , vol.120 , pp. 3418
    • van Ryn, J.1    Litzenburger, T.2    Gan, G.F.3    Coble, K.4    Schurer, J.5
  • 39
    • 84889688116 scopus 로고    scopus 로고
    • PHARMAC. [Cited 29 Oct 2013.] Available from
    • PHARMAC. [Cited 29 Oct 2013.] Available from URL: http://www.pharmac.govt.nz/2011/06/10/dabigatran%20bleeding%20management.pdf
  • 40
    • 84889662394 scopus 로고    scopus 로고
    • Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Dabigatran (Pradaxa®). [Cited 29 Oct 2013.] Available from
    • Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Dabigatran (Pradaxa®). [Cited 29 Oct 2013.] Available from URL: http://www.health.qld.gov.au/qhcss/mapsu/documents/dabigatran_info.pdf
  • 41
    • 84889642333 scopus 로고    scopus 로고
    • Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Rivaroxaban (Xarelto®). [Cited 29 Oct 2013.] Available from URL:
    • Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Rivaroxaban (Xarelto®). [Cited 29 Oct 2013.] Available from URL: http://www.health.qld.gov.au/qhcss/mapsu/documents/rivaroxaban-guideline.pdf
  • 42
    • 84884512133 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with mechanical heart valves
    • Eikelboom JW, Connolly SJ, Brueckmann M etal. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013; 369: 1206-1214.
    • (2013) N. Engl. J. Med. , vol.369 , pp. 1206-1214
    • Eikelboom, J.W.1    Connolly, S.J.2    Brueckmann, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.